NIH’s Therapeutic Management of Patients with COVID-19 & Some Unanswered Questions About Disturbing Chasm

NIH’s Therapeutic Management of Patients with COVID-19 & Some Unanswered Questions About Disturbing Chasm

The National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines: Therapeutic Management of Patients with COVID-19 guidelines highlighting recommended therapeutic treatment by COVID-19 disease severity level. As TrialSite has highlighted for months, there appears to be a distinct government bias in favor of certain kinds of COVID-19 fighting investments over others regarding investigational treatments. For example, the NIH has overwhelmingly focused research investment on vaccine candidates as well as novel monoclonal antibodies that have much yet to prove, as they acknowledge in the guidelines. This research translates into over $12.2 billion in Operation Warp Speed capital outlay, not including hundreds of millions more in NIH (ACTIV) sponsorship of clinical trials. When analyzing this spend, minute expenditure has gone into repurposing existing low cost and widely available therapies. So, well over $1 billion of taxpayer capital has been injected into clinical trials, manufacturing support and purchases of highly investigational monoclonal antibody products alone. As TrialSite and others have communicated, this class of experimental product raises sign...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee